Roche Diagnostics India has introduced a groundbreaking advancement in healthcare with the launch of its point-of-care NT-proBNP test, specifically designed to screen diabetes patients for cardiovascular diseases (CVD) such as heart failure (HF).
Roche Diagnostics India's NT-proBNP test on the cobas h 232 system addresses this critical gap by facilitating early detection and intervention.
Rishubh Gupta, Managing Director of Roche Diagnostics India and Neighbouring markets, reiterated the company's commitment to patient-centric solutions.
The introduction of the NT-proBNP test for diabetics at point-of-care represents a significant milestone in proactive and personalised healthcare for T2D patients.
Roche Diagnostics India reaffirms its commitment to empowering healthcare professionals and enhancing patient outcomes through innovative solutions.
Roche Diagnostics India has introduced a groundbreaking advancement in healthcare with the launch of its point-of-care NT-proBNP test, specifically designed to screen diabetes patients for cardiovascular diseases (CVD) such as heart failure (HF). This innovative solution aims to enhance testing efficiency and improve disease management, bringing transformative benefits to patient care.
The NT-proBNP biomarker, now available exclusively on Roche's cobas h 232 system, facilitates faster and more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D). By enabling testing closer to clinics, Roche Diagnostics India aims to revolutionise patient care and bridge critical gaps in disease detection and intervention.
Diabetes presents a significant health challenge globally, with India being notably affected. As the diabetes capital of the world, India hosts over 101 million individuals living with the disease, according to recent findings by the Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) national cross-sectional study.
Moreover, individuals with diabetes face a heightened risk of developing CVD, with up to 46 per cent experiencing CVD in their lifetime, contributing to approximately 50 per cent of mortality in T2D patients. Alarmingly, statistics indicate that 30 per cent of diabetic patients develop HF during their lifetime, with associated mortality risks up to 8 times higher compared to those without HF.
The challenge lies in the nonspecific symptoms of HF, often leading to late-stage detection. Roche Diagnostics India's NT-proBNP test on the cobas h 232 system addresses this critical gap by facilitating early detection and intervention. This proactive approach empowers clinicians to identify high-risk T2D patients and initiate timely treatment discussions, ultimately leading to improved patient outcomes.
Sanjay Kalra, Chief Endocrinologist at Bharti Hospital, Karnal, India, lauded the incorporation of NT-proBNP testing into primary care settings as a significant stride in diabetes care. He emphasised the importance of early HF risk assessment in T2D patients, highlighting the potential for improved outcomes and patient well-being.
Rishubh Gupta, Managing Director of Roche Diagnostics India and Neighbouring markets, reiterated the company's commitment to patient-centric solutions. He underscored Roche's dedication to advancing healthcare through innovation, emphasising the significance of the extended claim on the NT-proBNP test for diabetes at point-of-care in empowering clinicians and improving patient outcomes.
The introduction of the NT-proBNP test for diabetics at point-of-care represents a significant milestone in proactive and personalised healthcare for T2D patients. Roche Diagnostics India reaffirms its commitment to empowering healthcare professionals and enhancing patient outcomes through innovative solutions.
